KLOW Blend 80mg— Research Protocol

Quickstart Highlights

KLOW is a multi-peptide blend combining TB-500 (10 mg), BPC-157 (10 mg), KPV (10 mg), and GHK-Cu (50 mg) for a total of 80 mg per vial. TB-500 (synthetic thymosin beta-4) promotes wound healing, angiogenesis, and tissue repair^[1][2]. BPC-157 exhibits regenerative properties with preclinical evidence supporting tendon, ligament, and muscle healing^[3][4]. KPV is an anti-inflammatory tripeptide that modulates NF-κB signaling^[5][6]. GHK-Cu supports collagen synthesis, wound healing, and tissue regeneration^[7][8]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

• Reconstitute: Add 3.0 mL bacteriostatic water → ~26.7 mg/mL total concentration.
• Component concentrations: TB-500, BPC-157, KPV each at ~3.33 mg/mL; GHK-Cu at ~16.7 mg/mL.
• Easy measuring: At 26.7 mg/mL total, 1 unit = 0.01 mL ≈ 267 mcg total peptide on a U-100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Dosing & Reconstitution Guide

Standard / Gradual Approach (3 mL = ~26.7 mg/mL Total)

This multi-peptide blend provides synergistic regenerative, anti-inflammatory, and tissue-repair support. The following titration schedule allows gradual introduction of each component.

Phase	Dose	Units (per injection)
Weeks 1–2	TB-500: 250 mcg | BPC-157: 250 mcg | KPV: 250 mcg | GHK-Cu: 1.25 mg	7.5 units (0.075 mL)
Weeks 3–4	TB-500: 500 mcg | BPC-157: 500 mcg | KPV: 500 mcg | GHK-Cu: 2.5 mg	15 units (0.15 mL)
Weeks 5–8	TB-500: 750 mcg | BPC-157: 750 mcg | KPV: 750 mcg | GHK-Cu: 3.75 mg	22.5 units (0.225 mL)
Weeks 9–12 (Maintenance)	TB-500: 500 mcg | BPC-157: 500 mcg | KPV: 500 mcg | GHK-Cu: 2.5 mg	15 units (0.15 mL)

Frequency: Inject once daily subcutaneously. This schedule uses a 3.0 mL dilution to maintain measurable volumes. For ≤10-unit (≤0.10 mL) administrations during initial weeks, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl/roll until dissolved (do not shake).
4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Syringe Math Reference

With 3.0 mL reconstitution volume and 80 mg total peptide:

• Total concentration: 26.67 mg/mL (26,667 mcg/mL)
• TB-500: 3.33 mg/mL → 33.3 mcg per unit
• BPC-157: 3.33 mg/mL → 33.3 mcg per unit
• KPV: 3.33 mg/mL → 33.3 mcg per unit
• GHK-Cu: 16.67 mg/mL → 166.7 mcg per unit
• 1 unit (0.01 mL) = 33.3 mcg each of TB-500, BPC-157, KPV + 166.7 mcg GHK-Cu

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

• Peptide Vials (KLOW, 80 mg each):
  • 8 weeks ≈ 3 vials
  • 12 weeks ≈ 4 vials
  • 16 weeks ≈ 5 vials

• Insulin Syringes (U-100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes

• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
  • 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
  • 16 weeks (5 vials): 15 mL → 2 × 10 mL bottles

• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
  • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
  • 16 weeks: 224 swabs → recommend 3 × 100-count boxes

Protocol Overview

Protocol Overview

Concise summary of the once-daily regimen.

• Goal: Support tissue repair, reduce inflammation, and promote regeneration through synergistic peptide action^[1][3][5][7].
• Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
• Dose Range: Gradual titration from low to moderate doses based on individual response.
• Reconstitution: 3.0 mL per 80 mg vial (~26.7 mg/mL total) for accurate unit measurements.
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach.

• Start: 7.5 units daily (0.075 mL) for initial assessment period.
• Increase: Progress to 15 units by Week 3, then 22.5 units by Week 5 as tolerated.
• Maintenance: 15 units daily for extended protocols.
• Frequency: Once per day (subcutaneous).
• Cycle Length: 8–12 weeks; optional extension to 16 weeks.
• Timing: Any consistent time; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure^[9].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 14–28 days and avoid freeze–thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

How It Works

KLOW combines four peptides with complementary mechanisms of action:

• TB-500 (Thymosin Beta-4): Promotes angiogenesis, cell migration, and tissue repair by regulating actin, a key protein in cell structure^[1]. Preclinical studies demonstrate accelerated wound healing, reduced inflammation, and tissue regeneration^[2].
• BPC-157: A gastric pentadecapeptide that supports tendon, ligament, and muscle healing through enhanced angiogenesis and growth factor modulation^[3]. Animal studies show favorable tissue repair outcomes^[4].
• KPV: A C-terminal tripeptide fragment of α-MSH with potent anti-inflammatory properties. It inhibits NF-κB signaling and reduces pro-inflammatory cytokines without melanotropic effects^[5][6].
• GHK-Cu: A naturally occurring copper peptide that stimulates collagen and elastin synthesis, promotes wound healing, and modulates gene expression related to tissue remodeling^[7][8].

Potential Benefits & Side Effects

Observations from preclinical and early-stage research.

Potential Benefits

• Accelerated tissue repair and wound healing through multiple complementary pathways^[1][3].
• Reduced inflammation via NF-κB inhibition and cytokine modulation^[5][7].
• Enhanced collagen synthesis and connective tissue support^[8].
• Promotion of angiogenesis and improved blood flow to healing tissues^[2].
• Potential support for musculoskeletal recovery and joint health^[3].

Possible Side Effects

• Mild injection-site reactions (redness, irritation) may occur with subcutaneous administration.
• Occasional lightheadedness reported with some peptides due to vasodilatory effects.
• Limited human clinical data; most safety observations derive from preclinical studies^[4].

References

• PubMedThymosin beta 4 accelerates wound healing (Philp et al., 1999)
• PubMedThymosin β4 promotes dermal healing in preclinical models and clinical trials
• PMCEmerging use of BPC-157 in orthopaedic sports medicine: systematic review
• PMCPharmacokinetics, distribution, metabolism, and excretion of BPC-157 in rats and dogs
• PMCPepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
• PMCOrally targeted delivery of tripeptide KPV via HA-functionalized nanoparticles alleviates ulcerative colitis
• PMCRegenerative and protective actions of the GHK-Cu peptide in light of new gene data
• PMCGHK peptide as a natural modulator of multiple cellular pathways in skin regeneration
• Sigma-AldrichHandling and storage guidelines for peptides and proteins
• CDCVaccine administration: subcutaneous injection technique guidelines
• CDCVaccine administration best practices (aspiration not recommended for SC injections)
• NCBI BookshelfChapter 18: Administration of parenteral medications (injection technique)
• PubMedThymosin β4: a multi-functional regenerative peptide (basic properties and clinical applications)
• PMCThe potential of GHK as an anti-aging peptide